Lantheus Holdings, Inc.
LNTHHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeLantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The $6.56B market capitalization puts LNTH squarely in mid-cap range for its industry. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Market Cap
$6.56B
Beta
-0.03
P/E (TTM)
24.03
P/E (Fwd)
15.75
EPS (TTM)
$4.18
EPS (Fwd)
$6.38
ROE
22.2%
ROA
8.4%
Cash
$593.3M
Total Debt
$625.0M
Free CF
$451.7M
52W Change
92.3%
Annual Financials
Cash vs Debt
Where LNTH stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, LNTH finished 12.82% above its 150-day moving average ($89.36) and 22.16% above its 200-day moving average ($82.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LNTH overbought or oversold?
At the August 27, 2026 close, LNTH's RSI(14) was 46.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $593.3M in cash, though total debt stands at $625.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $451.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 22.2%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $425.2M (2021) to $1.54B (2025), reflecting a 263% increase over the period.
With a beta below 0.7, Lantheus Holdings, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Lantheus Holdings, Inc. and its sector.